Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension study of topical omiganan in papulopustular rosacea
NL-OMON42492Phase 3Not yet recruiting
- Sponsor
- Biofrontera
- Start
- Dec 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of omiganan in rosacea and papulopustular rosacea, sponsored by Biofrontera. Planned start Dec 2015; status: not yet recruiting.
02
Drugs
omiganan
03
Conditions
rosaceapapulopustular rosacea
Beyond the preview
Go deeper on NL-OMON42492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42492.